Fortress Biotech (NASDAQ:FBIOP – Get Free Report) is anticipated to announce its results before the market opens on Monday, August 17th. Analysts expect Fortress Biotech to announce earnings of ($0.20) per share and revenue of $18.30 million for the quarter.
Fortress Biotech Stock Performance
Fortress Biotech stock opened at $19.88 on Monday. The stock has a fifty day moving average price of $19.67 and a two-hundred day moving average price of $15.75. Fortress Biotech has a 52-week low of $6.27 and a 52-week high of $21.43.
Fortress Biotech Company Profile
Fortress Biotech, Inc (NASDAQ: FBIOP) is a biopharmaceutical company that acquires, develops and commercializes innovative therapeutics for the treatment of patients with serious diseases. Operating as a biotech accelerator, Fortress Biotech partners with experienced management teams to advance products from early-stage discovery through regulatory approval and commercial launch. Its diversified portfolio spans multiple therapeutic areas, including oncology, rare diseases, dermatology, ophthalmology and neuromuscular disorders.
The company’s business model centers on establishing and funding product-centric subsidiary companies, each focused on a specific drug candidate or therapy.
Read More
- Five stocks we like better than Fortress Biotech
- Albemarle’s Blowout Quarter Shows Why Lithium Still Matters
- Can DICK’S Turn Foot Locker Into a Winner?
- Why Dutch Bros Plunged Despite a Q2 Earnings Beat and Record Revenue
- Take-Two’s Q1 Results Leave GTA 6 Bulls Stuck in the Fog of War
Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
